The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Open accessAbstract
Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR s) and fibroblast growth factor receptors (FGFR s), recently demonstrated a treatment effect on overall survival by statistical confirmation of noninferiority to sorafenib in a phase 3 study of uHCC. Here, we investigated mechanisms underlying the antitumor activity of lenvatinib in preclinical HCC models. In vitro proliferation assay of nine human HCC cell lines showed that lenvatinib selectively inhibited proliferation of FGF signal‐activated HCC cells including FGF 19‐expressing Hep3B2.1‐7. Lenvatinib suppressed phosphorylation of FRS 2, a substrate of FGFR 1–4, in these cells in a concentration‐dependent manner. Lenvatinib inhibited in vivo tumor growth in Hep3B2.1‐7 and SNU‐398 xenografts and decreased phosphorylation of FRS 2 and Erk1/2 within the tumor tissues. Lenvatinib also exerted antitumor activity and potently reduced tumor microvessel density in PLC/PRF/5 xenograft model and two HCC patient‐derived xenograft models. These results suggest that lenvatinib has antitumor activity consistently across diverse HCC models, and that targeting of tumor FGF signaling pathways and anti‐angiogenic activity underlies its antitumor activity against HCC tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
Self-citationMatsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5270 · Cited by 530
Self-citationYamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507
Self-citationTohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
Self-citationSawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R. W., Yee, H., Stein, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 436
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351
Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 313
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
Self-citationDistinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
Self-citationDesnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
French, D. M., Lin, B. C., Wang, M., Adams, C., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
Welte, T., Kim, I. S., Tian, L., Gao, X., Wang, H., Li, J., Holdman, X. B., Herschkowitz, J. I., Pond, A., Xie, G., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3355 · Cited by 216
Vascular Changes in Hepatocellular Carcinoma
Yang, Z. F., & Poon, R. T. P. (2008) · The Anatomical Record · doi:10.1002/ar.20668 · Cited by 211
Tovar, V., Cornella, H., Moeini, A., Vidal, S., Hoshida, Y., Sia, D., Peix, J., Cabellos, L., Alsinet, C., Torrecilla, S., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-309501 · Cited by 206
Miura, S., Mitsuhashi, N., Shimizu, H., Kimura, F., Yoshidome, H., Otsuka, M., Kato, A., Shida, T., Okamura, D., & Miyazaki, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-56 · Cited by 193
Courau, T., Nehar-Belaid, D., Flórez, L. V., Levacher, B., Vazquez, T., Brimaud, F., Bellier, B., & Klatzmann, D. (2016) · JCI Insight · doi:10.1172/jci.insight.85974 · Cited by 143
Gauglhofer, C., Sagmeister, S., Schrottmaier, W. C., Fischer, C., Rodgarkia‐Dara, C., Mohr, T. T., Stättner, S., Bichler, C., Kandioler, D., Wrba, F., et al. (2010) · Hepatology · doi:10.1002/hep.24099 · Cited by 130
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab
Finn, R. S., & Zhu, A. X. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.6 · Cited by 117
Hyeon, J., Ahn, S., Lee, J. J., Song, D. H., & Park, C.-K. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2609-x · Cited by 103
Zhu, A. X. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.014 · Cited by 82
Gu, Q., Zhang, B., Sun, H., Xu, Q., Tan, Y., Wang, G., Luo, Q., Xu, W., Yang, S., Li, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3969 · Cited by 80
Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma
Repana, D., & Ross, P. J. (2015) · Diseases · doi:10.3390/diseases3040294 · Cited by 80
Matsuki, M., Adachi, Y., Ozawa, Y., Kimura, T., Hoshi, T., Okamoto, K., Tohyama, O., Mitsuhashi, K. O., Yamaguchi, A., Matsui, J., et al. (2017) · Cancer Science · doi:10.1111/cas.13169 · Cited by 66
Self-citationWang, L., Park, H., Chhim, S., Ding, Y., Jiang, W., Queen, C., & Kim, K. J. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0813 · Cited by 60
Futami, T., Okada, H., Kihara, R., Kawase, T., Nakayama, A., Suzuki, T., Kameda, M., Shindoh, N., Terasaka, T., Hirano, M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0188 · Cited by 41
Paur, J., Nika, L., Maier, C., Moscu‐Gregor, A., Kostka, J., Huber, D., Mohr, T. T., Heffeter, P., Schrottmaier, W. C., Kappel, S., et al. (2015) · Hepatology · doi:10.1002/hep.28023 · Cited by 40
Xin, H., Wang, K., Hu, G., Xie, F., Ouyang, K., Tang, X., Wang, M., Wen, D., Zhu, Y. Z., & Qin, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085308 · Cited by 40
Schmidt, B. H., Wei, L., DePeralta, D. K., Hoshida, Y., Tan, P. S., Sun, X., Sventek, J. P., Lanuti, M. D., Tanabe, K. K., & Fuchs, B. C. (2015) · International Journal of Cancer · doi:10.1002/ijc.29893 · Cited by 38
Iwata, H., Imamura, S., Hori, A., Hixon, M. S., Kimura, H., & Miki, H. (2010) · Biochemistry · doi:10.1021/bi101777f · Cited by 37
Matsui, J. (2016) · Global Journal of Cancer Therapy · doi:10.17352/gjct.000009 · Cited by 12
Self-citation
Cited by
EGFR activation limits the response of liver cancer to lenvatinib
Jin, H., Shi, Y., Lv, Y., Yuan, S., Ramirez, C. F. A., Lieftink, C., Wang, L., Wang, S., Wang, C., Dias, M. H., et al. (2021) · Nature · doi:10.1038/s41586-021-03741-7 · Cited by 440
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Self-citationLenvatinib: A Review in Hepatocellular Carcinoma
Al-Salama, Z. T., Syed, Y. Y., & Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-019-01116-x · Cited by 318
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Zhao, Y., Zhang, Y.-N., Wang, K.-T., & Chen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188391 · Cited by 278
Metadata
- Authors
- Matsuki, M., Hoshi, T., Yamamoto, Y., Ikemori‐Kawada, M., Minoshima, Y., Funahashi, Y., & Matsui, J.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2018-05-07
- Volume
- 7
- Issue
- 6
- Pages
- 2641-2653
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W2800499107
- Cited by
- 266
- References
- 45
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.